FDA Extends PDUFA Date for Revumenib in KMT2A-Rearranged Acute Leukemia
The FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for the new drug application (NDA) seeking the approval of revumenib (SNDX-5613) for the treatment of adult and pediatric patients with relapsed/refractory KMT2A- …